UK Renal Registry, Bristol, UK.
Nephron Clin Pract. 2012;120 Suppl 1:c219-32. doi: 10.1159/000342855. Epub 2012 Sep 1.
The British Association for Paediatric Nephrology Registry was established to analyse data related to renal replacement therapy (RRT) for children. The registry receives data from the 13 paediatric nephrology centres in the UK.
To provide centre specific data so that individual centres can reflect on the contribution that their data makes to the national picture and to determine the extent to which their patient parameters meet nationally agreed audit standards for the management of children with established renal failure.
Data returns have been a mixture of electronic and paper returns. Data were analysed to calculate summary statistics and where applicable the percentage achieving an audit standard. The standards used were those set out by the Renal Association and the National Institute for Health and Clinical Excellence.
Anthropometric data confirmed that children receiving RRT are short compared to healthy peers. Amongst patients with a height z-score of <2SD between 2000 and 2010, 27% were receiving growth hormone if they were on dialysis compared to 10% if they had a functioning transplant. Blood pressure was higher in children receiving RRT than in healthy children with wide inter-centre variation. The percentage of patients achieving the treatment standards for haemoglobin and ferritin has gradually increased over the last decade, more noticeably in dialysis patients. Analysis by age showed that the proportion of children with a haemoglobin below the standard was greatest for the under 5 years age group irrespective of RRT modality. The control of renal bone disease remained challenging.
Optimizing growth in children on RRT remains challenging and the control of bone biochemistry in children on dialysis is imperfect. However there is some room for optimism as this year's data shows an improving trend in the control of anaemia and systolic blood pressure.
英国儿科肾脏病学会注册处成立的目的是分析与儿童肾脏替代治疗（RRT）相关的数据。该注册处接收来自英国 13 个儿科肾脏病中心的数据。
提供特定中心的数据，以便各个中心能够反思其数据对国家整体情况的贡献，并确定其患者参数在多大程度上符合国家商定的用于管理已确诊肾衰竭儿童的审计标准。
数据报告既有电子报告也有纸质报告。对数据进行分析以计算汇总统计数据，在适用的情况下计算符合审计标准的百分比。使用的标准是由肾脏协会和国家卫生与临床优化研究所制定的标准。
人体测量数据证实，接受 RRT 的儿童比健康同龄人矮小。在身高 z 分数<2SD 的患者中，2000 年至 2010 年间，接受透析治疗的患者中有 27%接受了生长激素治疗，而接受功能移植的患者中只有 10%接受了生长激素治疗。接受 RRT 的儿童的血压高于健康儿童，且各中心之间的差异较大。在过去十年中，接受 RRT 的患者达到血红蛋白和铁蛋白治疗标准的比例逐渐增加，透析患者的增幅更为明显。按年龄分析显示，无论 RRT 方式如何，血红蛋白低于标准的儿童比例在 5 岁以下年龄组最大。控制肾脏骨疾病仍然具有挑战性。
优化接受 RRT 治疗的儿童的生长仍然具有挑战性，透析儿童的骨生化控制并不完美。然而，今年的数据显示贫血和收缩压控制方面有改善的趋势，这让人感到有些乐观。
